The phase Ib study GO30140 evaluating atezolizumab monotherapy compared to combination of atezolizumab and the anti-VEGF bevacizumab in patients with advanced HCC, showed a median PFS of 3.4 months in the monotherapy arm, compared to 5.6 months in the combination arm (HR 0.55, p = 0.018) [65]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.